Market capitalization | €79.49m |
Enterprise Value | €81.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 9.89 |
EV/Sales (TTM) EV/Sales | 1.04 |
P/S ratio (TTM) P/S ratio | 1.01 |
P/B ratio (TTM) P/B ratio | 3.44 |
Revenue growth (TTM) Revenue growth | 7.83% |
Revenue (TTM) Revenue | €78.82m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
1 Analyst has issued a forecast Vita 34:
1 Analyst has issued a forecast Vita 34:
Jun '24 |
+/-
%
|
||
Net Profit | -1.41 -1.41 |
18%
18%
|
|
Depreciation and Amortization | 2.26 2.26 |
3%
3%
|
|
Stock Compensation | - - |
-
|
|
Operating Cash Flow | 0.35 0.35 |
70%
70%
|
|
Investments | 0.40 0.40 |
47%
47%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -0.01 -0.01 |
102%
102%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The firm collects, processes, and stores stem cells from umbilical cord blood and tissue, and develops cell therapy processes. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.
Head office | Germany |
CEO | Jakub Baran |
Employees | 745 |
Founded | 1997 |
Website | www.vita34.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.